Leerink Partnrs Has Negative Outlook of TNDM FY2028 Earnings

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Equities research analysts at Leerink Partnrs decreased their FY2028 earnings estimates for Tandem Diabetes Care in a research report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will post earnings of $0.00 per share for the year, down from their prior forecast of $0.01. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.73) per share.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.08. The firm had revenue of $243.97 million for the quarter, compared to analysts’ expectations of $224.14 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company’s quarterly revenue was up 31.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.38) EPS.

Several other research analysts have also weighed in on the stock. Canaccord Genuity Group dropped their price objective on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Canaccord Genuity Group assumed coverage on shares of Tandem Diabetes Care in a research report on Thursday, August 8th. They set a “buy” rating and a $57.00 price objective on the stock. UBS Group upgraded shares of Tandem Diabetes Care to a “hold” rating in a research note on Friday, August 2nd. Robert W. Baird dropped their price target on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a research note on Thursday, November 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $55.00 price objective (up previously from $50.00) on shares of Tandem Diabetes Care in a research note on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and an average target price of $54.25.

Tandem Diabetes Care Stock Performance

Shares of TNDM stock opened at $30.42 on Tuesday. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -16.19 and a beta of 1.36. Tandem Diabetes Care has a 1-year low of $18.45 and a 1-year high of $53.69. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The stock’s fifty day simple moving average is $36.16 and its 200-day simple moving average is $41.23.

Insiders Place Their Bets

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the transaction, the director now owns 195,190 shares of the company’s stock, valued at $5,855,700. This represents a 4.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 2.20% of the company’s stock.

Institutional Trading of Tandem Diabetes Care

Institutional investors and hedge funds have recently modified their holdings of the company. McIlrath & Eck LLC bought a new position in Tandem Diabetes Care in the third quarter worth $52,000. Coldstream Capital Management Inc. raised its stake in shares of Tandem Diabetes Care by 14.0% in the 3rd quarter. Coldstream Capital Management Inc. now owns 6,212 shares of the medical device company’s stock valued at $263,000 after buying an additional 762 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Tandem Diabetes Care by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,525,816 shares of the medical device company’s stock worth $64,722,000 after acquiring an additional 18,187 shares during the period. M&T Bank Corp lifted its holdings in shares of Tandem Diabetes Care by 1.7% during the 3rd quarter. M&T Bank Corp now owns 51,835 shares of the medical device company’s stock worth $2,199,000 after acquiring an additional 858 shares during the period. Finally, State Street Corp boosted its position in shares of Tandem Diabetes Care by 3.2% during the 3rd quarter. State Street Corp now owns 2,655,736 shares of the medical device company’s stock valued at $112,630,000 after acquiring an additional 83,172 shares in the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.